These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30961437)

  • 1. Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature.
    Stein J; Milhem M; Vaena D
    J Oncol Pharm Pract; 2020 Jan; 26(1):232-235. PubMed ID: 30961437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
    Keisner SV; Shah SR
    Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe hyperglycaemia following pazopanib treatment: The role of drug-drug-gene interactions in a patient with metastatic renal cell carcinoma-A case report.
    Kuruc Poje D; Božina N; Šimičević L; Žabić I
    J Clin Pharm Ther; 2020 Aug; 45(4):628-631. PubMed ID: 32369219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pazopanib.
    Bukowski RM; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 Jan; 9(1):17-8. PubMed ID: 20043026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
    Brotelle T; Bay JO
    Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib outscores sunitinib on tolerability.
    Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
    Koc G; Wang X; Luo Y
    Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
    Sneed GT; Lee S; Brown JN; Hammond JM
    Clin Genitourin Cancer; 2019 Dec; 17(6):419-424. PubMed ID: 31585694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib: a review of its use in the management of advanced renal cell carcinoma.
    McCormack PL
    Drugs; 2014 Jul; 74(10):1111-25. PubMed ID: 24935162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
    Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
    Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib in renal cell carcinoma.
    Ward JE; Stadler WM
    Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma.
    Sternberg CN; Donskov F; Haas NB; Doehn C; Russo P; Elmeliegy M; Baneyx G; Banerjee H; Aimone P; Motzer RJ
    Clin Cancer Res; 2018 Jul; 24(13):3005-3013. PubMed ID: 29330204
    [No Abstract]   [Full Text] [Related]  

  • 17. Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
    Koca S; Beşiroğlu M; Özçelik M; Karaca M; Bilici M; Hacıoğlu B; Doğu GG; Kaplan NB; Oruç Z; Aydın D; Dane F
    J Oncol Pharm Pract; 2021 Apr; 27(3):541-546. PubMed ID: 32419618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.
    Heath EI; Forman K; Malburg L; Gainer S; Suttle AB; Adams L; Ball H; LoRusso P
    Invest New Drugs; 2012 Aug; 30(4):1566-74. PubMed ID: 21811833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
    Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M
    Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
    Kasper B; Hohenberger P
    Future Oncol; 2011 Dec; 7(12):1373-83. PubMed ID: 22112314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.